Skip Intro

Ribon Therapeutics

In February 2016, Deerfield invested in Ribon Therapeutics’ $24 million Series A preferred financing. Ribon is a discovery stage biotechnology company focused on a specific part of Poly Polymerases (PARPs) called monoPARP (mono ADP-ribose polymerase). These proteins are potential inhibitors to block cancer cells’ fundamental ability to survive under stress.